EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Early Enzymatic Burn Debridement: Results of the DETECT Multicenter Randomized Controlled Trial

Yaron Shoham iD, Lior Rosenberg, William Hickerson iD, Jeremy Goverman, Narayan Iyer, Julio Barrera-Oro, Bretislav Lipovy iD, Stan Monstrey, Sigrid Blome-Eberwein, Lucy A Wibbenmeyer, Martin Scharpenberg iD, Adam J Singer iD

Journal of Burn Care & Research · 04.03.2024 · 45 (2) · 297-307

DOI: 10.1093/jbcr/irad142 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Burn Care & Research, online erschienen am 16.09.2023. Verfasst von Yaron Shoham und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery and Burn Unit, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-S…. Hauptthemen laut MEDLINE: Burns, Wound Healing. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since 1970 surgeons have managed deep burns by surgical debridement and autografting. We tested the hypothesis that enzymatic debridement with NexoBrid would remove the eschar reducing surgery and achieve comparable long-term outcomes as standard of care (SOC). In this Phase 3 trial, we randomly assigned adults with deep burns (covering 3–30% of total body surface area [TBSA]) to NexoBrid, surgical or nonsurgical SOC, or placebo Gel Vehicle (GV) in a 3:3:1 ratio. The primary endpoint was complete eschar removal (ER) at the end of the debridement phase. Secondary outcomes were need for surgery, time to complete ER, and blood loss. Safety endpoints included wound closure and 12 and 24-months cosmesis on the Modified Vancouver Scar Scale. Patients were randomized to NexoBrid (n = 75), SOC (n = 75), and GV (n = 25). Complete ER was higher in the NexoBrid versus the GV group (93% vs 4%; P < .001). Surgical excision was lower in the NexoBrid vs the SOC group (4% vs 72%; P < .001). Median time to ER was 1.0 and 3.8 days for the NexoBrid and SOC respectively (P < .001). ER blood loss was lower in the NexoBrid than the SOC group (14 ± 512 mL vs 814 ± 1020 mL, respectively; P < .0001). MVSS scores at 12 and 24 months were noninferior in the NexoBrid versus SOC groups (3.7 ± 2.1 vs 5.0 ± 3.1 for the 12 months and 3.04 ± 2.2 vs 3.30 ± 2.76 for the 24 months). NexoBrid resulted in early complete ER in >90% of burn patients, reduced surgery and blood loss. NexoBrid was safe and well tolerated without deleterious effects on wound closure and scarring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BurnsWound HealingAdultHumansCicatrixDebridement

Stichwörter der Autor:innen

burnsenzymatic debridementescharexcisiongraftingsurgery

Autor:innen und Institutionen

  • Department of Plastic Surgery and Burn Unit, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba 8400711, Israel.
  • Department of Plastic Surgery, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
  • Department of Medicine, Firefighters Regional Burn Center, Regional One Health, Memphis, TN 38163, USA.
  • Department of Surgery, Sumner Redstone Burn Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Burn and Blast Medical Countermeasures Program, Division of Chemical, Biological, Radiological/Nuclear Countermeasures (CBRN), Biomedical Advanced Research and Development Authority (BARDA), Administration for Preparedn…
  • Department of Burns and Plastic Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno 60300, Czech Republic.

ORCID-Profile: Yaron Shoham, William Hickerson, Bretislav Lipovy, Martin Scharpenberg, Adam J Singer

Förderung

  • Biomedical Advanced Research and Development Authority
  • Administration for Strategic Preparedness and Response
  • U.S. Department of Health and Human Services

Zitieren

APA

Shoham, Y., Rosenberg, L., Hickerson, W., Goverman, J., Iyer, N., Barrera-Oro, J., Lipovy, B., Monstrey, S., Blome-Eberwein, S., Wibbenmeyer, L. A., Scharpenberg, M., & Singer, A. J. (2024). Early Enzymatic Burn Debridement: Results of the DETECT Multicenter Randomized Controlled Trial. Journal of Burn Care & Research, 45(2), 297-307. https://doi.org/10.1093/jbcr/irad142

Vancouver

Shoham Y, Rosenberg L, Hickerson W, Goverman J, Iyer N, Barrera-Oro J, et al. Early Enzymatic Burn Debridement: Results of the DETECT Multicenter Randomized Controlled Trial. Journal of Burn Care & Research. 2024;45(2):297-307. doi:10.1093/jbcr/irad142

BibTeX
@article{Shoham2024,
  author = {Shoham, Yaron and Rosenberg, Lior and Hickerson, William and Goverman, Jeremy and Iyer, Narayan and Barrera-Oro, Julio and Lipovy, Bretislav and Monstrey, Stan and Blome-Eberwein, Sigrid and Wibbenmeyer, Lucy A and Scharpenberg, Martin and Singer, Adam J},
  title = {Early Enzymatic Burn Debridement: Results of the DETECT Multicenter Randomized Controlled Trial},
  journal = {Journal of Burn Care & Research},
  year = {2024},
  volume = {45},
  number = {2},
  pages = {297--307},
  doi = {10.1093/jbcr/irad142}
}
Kostenlos starten →